The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in treating patients with acne vulgaris.

Inclusion Criteria:

• Presence of acne vulgaris on the face and neck/trunk
• Presence of inflammatory and non-inflammatory lesions on the face

Exclusion Criteria:

• Presence of any skin condition on the face that could interfere with clinical evaluations
• Use of any systemic antibiotics or corticosteroids within 4 weeks prior to the Baseline visit
• Use of any systemic retinoids, such as isotretinoin, within 3 months prior to the Baseline visit
• Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period